Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERICA infliximab histologic and endoscopic remission study in ulcerative colitis
2009-013890-16Phase 4Completed
- Sponsor
- GEDiCube
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in autoimmune colitis, sponsored by GEDiCube. Primary endpoints: Histological remission at week 8, Time to first documented histological remission and 2 more. Started Dec 2009; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2009-013890-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013890-16.